Table 3

Differences in response rates (per cent of patients with 95% confidence intervals) at the end of the two week treatment period compared with placebo (therapeutic gain) in the ranitidine 150 mg, omeprazole 10 mg (OM10), and omeprazole 20 mg (OM20) groups. “Primary response” indicates no need for management of dyspepsia; “No symptoms” indicates disappearance of all dyspeptic symptoms (intention to treat analysis)

RanitidineOM10OM20
H pylori positive
 Primary response (%)8.9  (−4.2–21.9)6.8  (-6.7–20.4)17.6  (4.2–31.0)3-160
 No symptoms (%)7.4 (−2.2–17.1)10.8 (0.4–21.1)3-150 19.6 (8.6–30.7)3-165 3-151
H pylorinegative
 Primary response (%)7.9 (−5.8–21.7)−1.1 (−14.4–12.3)5.5 (-8.0–19.1)
 No symptoms (%)12.7 (−0.7–26.2)10.5 (−2.1–23.1)16.7 (3.2–30.1)3-160
  • 3-150 p<0.05,

  • 3-160 p<0.025,

  • 3-165 p<0.001 compared with placebo;

  • 3-151 p<0.05 compared with ranitidine in the same H pylori group. All other differences within the sameH pylori group were not significant (p>0.05).